Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9

Fanny Kortüm, Rami Abou Jamra, Malik Alawi, Susan A. Berry, Guntram Borck, Katherine L. Helbig, Sha Tang, Dagmar Huhle, Georg Christoph Korenke, Malavika Hebbar, Anju Shukla, Katta M. Girisha, Maja Steinlin, Sandra Waldmeier-Wilhelm, Martino Montomoli, Renzo Guerrini, Johannes R. Lemke, Kerstin Kutsche

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pontocerebellar hypoplasia (PCH) represents a group of autosomal-recessive progressive neurodegenerative disorders of prenatal onset. Eleven PCH subtypes are classified according to clinical, neuroimaging and genetic findings. Individuals with PCH type 9 (PCH9) have a unique combination of postnatal microcephaly, hypoplastic cerebellum and pons, and hypoplastic or absent corpus callosum. PCH9 is caused by biallelic variants in AMPD2 encoding adenosine monophosphate deaminase 2; however, a homozygous AMPD2 frameshift variant has recently been reported in two family members with spastic paraplegia type 63 (SPG63). We identified homozygous or compound heterozygous AMPD2 variants in eight PCH-affected individuals from six families. The eight variants likely affect function and comprise one frameshift, one nonsense and six missense variants; seven of which were novel. The main clinical manifestations in the eight new patients and 17 previously reported individuals with biallelic AMPD2 variants were postnatal microcephaly, severe global developmental delay, spasticity, and central visual impairment. Brain imaging data identified hypomyelination, hypoplasia of the cerebellum and pons, atrophy of the cerebral cortex, complete or partial agenesis of the corpus callosum and the "figure 8" shape of the hypoplastic midbrain as consistent features. We broaden the AMPD2-related clinical spectrum by describing one individual without microcephaly and absence of the characteristic "figure 8" shape of the midbrain. The existence of various AMPD2 isoforms with different functions possibly explains the variability in phenotypes associated with AMPD2 variants: variants leaving some of the isoforms intact may cause SPG63, while those affecting all isoforms may result in the severe and early-onset PCH9.

Original languageEnglish
Pages (from-to)695-708
Number of pages14
JournalEuropean Journal of Human Genetics
Volume26
Issue number5
DOIs
Publication statusPublished - 01-05-2018

Fingerprint

Microcephaly
Protein Isoforms
Pons
Paraplegia
Mesencephalon
Neuroimaging
Cerebellum
Adenosine Deaminase
Corpus Callosum
Vision Disorders
Adenosine Monophosphate
Neurodegenerative Diseases
Cerebral Cortex
Atrophy
Phenotype
Pontocerebellar Hypoplasia

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Cite this

Kortüm, F., Jamra, R. A., Alawi, M., Berry, S. A., Borck, G., Helbig, K. L., ... Kutsche, K. (2018). Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9. European Journal of Human Genetics, 26(5), 695-708. https://doi.org/10.1038/s41431-018-0098-2
Kortüm, Fanny ; Jamra, Rami Abou ; Alawi, Malik ; Berry, Susan A. ; Borck, Guntram ; Helbig, Katherine L. ; Tang, Sha ; Huhle, Dagmar ; Korenke, Georg Christoph ; Hebbar, Malavika ; Shukla, Anju ; Girisha, Katta M. ; Steinlin, Maja ; Waldmeier-Wilhelm, Sandra ; Montomoli, Martino ; Guerrini, Renzo ; Lemke, Johannes R. ; Kutsche, Kerstin. / Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9. In: European Journal of Human Genetics. 2018 ; Vol. 26, No. 5. pp. 695-708.
@article{3dbf9e1d38994a1d812eda9acc80dcc6,
title = "Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9",
abstract = "Pontocerebellar hypoplasia (PCH) represents a group of autosomal-recessive progressive neurodegenerative disorders of prenatal onset. Eleven PCH subtypes are classified according to clinical, neuroimaging and genetic findings. Individuals with PCH type 9 (PCH9) have a unique combination of postnatal microcephaly, hypoplastic cerebellum and pons, and hypoplastic or absent corpus callosum. PCH9 is caused by biallelic variants in AMPD2 encoding adenosine monophosphate deaminase 2; however, a homozygous AMPD2 frameshift variant has recently been reported in two family members with spastic paraplegia type 63 (SPG63). We identified homozygous or compound heterozygous AMPD2 variants in eight PCH-affected individuals from six families. The eight variants likely affect function and comprise one frameshift, one nonsense and six missense variants; seven of which were novel. The main clinical manifestations in the eight new patients and 17 previously reported individuals with biallelic AMPD2 variants were postnatal microcephaly, severe global developmental delay, spasticity, and central visual impairment. Brain imaging data identified hypomyelination, hypoplasia of the cerebellum and pons, atrophy of the cerebral cortex, complete or partial agenesis of the corpus callosum and the {"}figure 8{"} shape of the hypoplastic midbrain as consistent features. We broaden the AMPD2-related clinical spectrum by describing one individual without microcephaly and absence of the characteristic {"}figure 8{"} shape of the midbrain. The existence of various AMPD2 isoforms with different functions possibly explains the variability in phenotypes associated with AMPD2 variants: variants leaving some of the isoforms intact may cause SPG63, while those affecting all isoforms may result in the severe and early-onset PCH9.",
author = "Fanny Kort{\"u}m and Jamra, {Rami Abou} and Malik Alawi and Berry, {Susan A.} and Guntram Borck and Helbig, {Katherine L.} and Sha Tang and Dagmar Huhle and Korenke, {Georg Christoph} and Malavika Hebbar and Anju Shukla and Girisha, {Katta M.} and Maja Steinlin and Sandra Waldmeier-Wilhelm and Martino Montomoli and Renzo Guerrini and Lemke, {Johannes R.} and Kerstin Kutsche",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/s41431-018-0098-2",
language = "English",
volume = "26",
pages = "695--708",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "5",

}

Kortüm, F, Jamra, RA, Alawi, M, Berry, SA, Borck, G, Helbig, KL, Tang, S, Huhle, D, Korenke, GC, Hebbar, M, Shukla, A, Girisha, KM, Steinlin, M, Waldmeier-Wilhelm, S, Montomoli, M, Guerrini, R, Lemke, JR & Kutsche, K 2018, 'Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9', European Journal of Human Genetics, vol. 26, no. 5, pp. 695-708. https://doi.org/10.1038/s41431-018-0098-2

Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9. / Kortüm, Fanny; Jamra, Rami Abou; Alawi, Malik; Berry, Susan A.; Borck, Guntram; Helbig, Katherine L.; Tang, Sha; Huhle, Dagmar; Korenke, Georg Christoph; Hebbar, Malavika; Shukla, Anju; Girisha, Katta M.; Steinlin, Maja; Waldmeier-Wilhelm, Sandra; Montomoli, Martino; Guerrini, Renzo; Lemke, Johannes R.; Kutsche, Kerstin.

In: European Journal of Human Genetics, Vol. 26, No. 5, 01.05.2018, p. 695-708.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9

AU - Kortüm, Fanny

AU - Jamra, Rami Abou

AU - Alawi, Malik

AU - Berry, Susan A.

AU - Borck, Guntram

AU - Helbig, Katherine L.

AU - Tang, Sha

AU - Huhle, Dagmar

AU - Korenke, Georg Christoph

AU - Hebbar, Malavika

AU - Shukla, Anju

AU - Girisha, Katta M.

AU - Steinlin, Maja

AU - Waldmeier-Wilhelm, Sandra

AU - Montomoli, Martino

AU - Guerrini, Renzo

AU - Lemke, Johannes R.

AU - Kutsche, Kerstin

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Pontocerebellar hypoplasia (PCH) represents a group of autosomal-recessive progressive neurodegenerative disorders of prenatal onset. Eleven PCH subtypes are classified according to clinical, neuroimaging and genetic findings. Individuals with PCH type 9 (PCH9) have a unique combination of postnatal microcephaly, hypoplastic cerebellum and pons, and hypoplastic or absent corpus callosum. PCH9 is caused by biallelic variants in AMPD2 encoding adenosine monophosphate deaminase 2; however, a homozygous AMPD2 frameshift variant has recently been reported in two family members with spastic paraplegia type 63 (SPG63). We identified homozygous or compound heterozygous AMPD2 variants in eight PCH-affected individuals from six families. The eight variants likely affect function and comprise one frameshift, one nonsense and six missense variants; seven of which were novel. The main clinical manifestations in the eight new patients and 17 previously reported individuals with biallelic AMPD2 variants were postnatal microcephaly, severe global developmental delay, spasticity, and central visual impairment. Brain imaging data identified hypomyelination, hypoplasia of the cerebellum and pons, atrophy of the cerebral cortex, complete or partial agenesis of the corpus callosum and the "figure 8" shape of the hypoplastic midbrain as consistent features. We broaden the AMPD2-related clinical spectrum by describing one individual without microcephaly and absence of the characteristic "figure 8" shape of the midbrain. The existence of various AMPD2 isoforms with different functions possibly explains the variability in phenotypes associated with AMPD2 variants: variants leaving some of the isoforms intact may cause SPG63, while those affecting all isoforms may result in the severe and early-onset PCH9.

AB - Pontocerebellar hypoplasia (PCH) represents a group of autosomal-recessive progressive neurodegenerative disorders of prenatal onset. Eleven PCH subtypes are classified according to clinical, neuroimaging and genetic findings. Individuals with PCH type 9 (PCH9) have a unique combination of postnatal microcephaly, hypoplastic cerebellum and pons, and hypoplastic or absent corpus callosum. PCH9 is caused by biallelic variants in AMPD2 encoding adenosine monophosphate deaminase 2; however, a homozygous AMPD2 frameshift variant has recently been reported in two family members with spastic paraplegia type 63 (SPG63). We identified homozygous or compound heterozygous AMPD2 variants in eight PCH-affected individuals from six families. The eight variants likely affect function and comprise one frameshift, one nonsense and six missense variants; seven of which were novel. The main clinical manifestations in the eight new patients and 17 previously reported individuals with biallelic AMPD2 variants were postnatal microcephaly, severe global developmental delay, spasticity, and central visual impairment. Brain imaging data identified hypomyelination, hypoplasia of the cerebellum and pons, atrophy of the cerebral cortex, complete or partial agenesis of the corpus callosum and the "figure 8" shape of the hypoplastic midbrain as consistent features. We broaden the AMPD2-related clinical spectrum by describing one individual without microcephaly and absence of the characteristic "figure 8" shape of the midbrain. The existence of various AMPD2 isoforms with different functions possibly explains the variability in phenotypes associated with AMPD2 variants: variants leaving some of the isoforms intact may cause SPG63, while those affecting all isoforms may result in the severe and early-onset PCH9.

UR - http://www.scopus.com/inward/record.url?scp=85042213582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042213582&partnerID=8YFLogxK

U2 - 10.1038/s41431-018-0098-2

DO - 10.1038/s41431-018-0098-2

M3 - Article

VL - 26

SP - 695

EP - 708

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 5

ER -